通过热休克蛋白90（HSP90）抑制癌症的分子进化。 - Suppr

Suppr

超能文献

Inhibiting the molecular evolution of cancer through HSP90.

作者信息

Martins Ana Sofia, Davies Faith E, Workman Paul

出版信息

Oncotarget. 2012 Oct;3(10):1054-6. doi: 10.18632/oncotarget.738.

DOI:10.18632/oncotarget.738

PMID:23175477

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3717948/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f0/3717948/ecc50666f8c6/oncotarget-03-1054-g001.jpg

相似文献

Inhibiting the molecular evolution of cancer through HSP90.通过热休克蛋白90（HSP90）抑制癌症的分子进化。

Oncotarget. 2012 Oct;3(10):1054-6. doi: 10.18632/oncotarget.738.

Preface.前言。

Adv Cancer Res. 2016;129:xiii-xv. doi: 10.1016/S0065-230X(16)30016-1.

Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.Hsp90 调节的替代策略用于癌症和其他疾病的治疗。

Curr Top Med Chem. 2009;9(15):1447-61. doi: 10.2174/156802609789895683.

Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.抑制热休克蛋白 90 的蛋白-蛋白相互作用作为一种针对癌症的新方法。

Eur J Med Chem. 2019 Sep 15;178:48-63. doi: 10.1016/j.ejmech.2019.05.073. Epub 2019 May 30.

Heat shock protein 90: a unique chemotherapeutic target.热休克蛋白90：一个独特的化疗靶点。

Semin Oncol. 2006 Aug;33(4):457-65. doi: 10.1053/j.seminoncol.2006.04.001.

Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1803-4. doi: 10.1097/01.JTO.0000407565.99405.91.

Heat shock protein 90 inhibitors as therapeutic agents.热休克蛋白 90 抑制剂作为治疗药物。

Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):313-36. doi: 10.2174/157489212801820066.

Hsp90 inhibitors as promising agents for radiotherapy.热休克蛋白 90 抑制剂作为放疗的有前途的药物。

J Mol Med (Berl). 2010 Mar;88(3):241-7. doi: 10.1007/s00109-009-0562-0. Epub 2009 Nov 28.

HSP90 inhibitors for cancer therapy and overcoming drug resistance.用于癌症治疗和克服耐药性的热休克蛋白90（HSP90）抑制剂

Adv Pharmacol. 2012;65:471-517. doi: 10.1016/B978-0-12-397927-8.00015-4.

Heat shock protein 90: the cancer chaperone.热休克蛋白90：癌症伴侣蛋白

J Biosci. 2007 Apr;32(3):517-30. doi: 10.1007/s12038-007-0051-y.

引用本文的文献

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance.以 HSP90 为靶点的癌症治疗新策略：作用机制与转化医学相关性研究。

Cells. 2022 Sep 6;11(18):2778. doi: 10.3390/cells11182778.

The Warburg effect and drug resistance.瓦伯格效应与耐药性。

Br J Pharmacol. 2016 Mar;173(6):970-9. doi: 10.1111/bph.13422. Epub 2016 Feb 18.

Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.将TRAIL与PI3激酶或HSP90抑制剂联合使用可通过抑制生存信号增强结肠癌细胞的凋亡。

Oncotarget. 2013 Aug;4(8):1185-98. doi: 10.18632/oncotarget.1162.

Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.靶向热休克因子1可使癌细胞对热休克蛋白90抑制敏感。

Oncotarget. 2013 Jun;4(6):816-29. doi: 10.18632/oncotarget.991.

本文引用的文献

Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase.热休克蛋白90在高危骨髓增生异常综合征中过表达，并与粘着斑激酶的高表达和激活相关。

Oncotarget. 2012 Oct;3(10):1158-68. doi: 10.18632/oncotarget.557.

The role of mutations in epigenetic regulators in myeloid malignancies.基因突变在髓系恶性肿瘤中表观遗传学调控中的作用。

Nat Rev Cancer. 2012 Sep;12(9):599-612. doi: 10.1038/nrc3343. Epub 2012 Aug 17.

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.骨髓增生异常综合征：2012 年诊断、风险分层和治疗更新。

Am J Hematol. 2012 Jul;87(7):692-701. doi: 10.1002/ajh.23264.

Hsp90 molecular chaperone inhibitors: are we there yet?热休克蛋白 90 分子伴侣抑制剂：我们成功了吗？

Clin Cancer Res. 2012 Jan 1;18(1):64-76. doi: 10.1158/1078-0432.CCR-11-1000.

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells.

Cell Stress Chaperones. 2008 Sep;13(3):357-64. doi: 10.1007/s12192-008-0035-3. Epub 2008 Apr 3.

Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes.

Haematologica. 2006 May;91(5):713-4.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.组蛋白脱乙酰酶抑制剂LBH589与热休克蛋白90抑制剂17-AAG联合使用对具有FLT-3激活突变的人慢性粒细胞白血病急变期细胞和急性髓细胞白血病细胞具有高活性。

Blood. 2005 Feb 15;105(4):1768-76. doi: 10.1182/blood-2004-09-3413. Epub 2004 Oct 28.

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.Hsp90抑制剂17-烯丙基氨基-17-去甲氧基格尔德霉素对信号转导的抑制作用会导致细胞生长停滞和凋亡。

Cancer Res. 2001 May 15;61(10):4003-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验